SomnoMed Limited (ASX:SOM)
0.6000
0.00 (0.00%)
Jun 5, 2026, 3:01 PM AEST
SomnoMed Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, SomnoMed stock has a consensus rating of "Strong Buy" and an average price target of $1.03. The average 1-year stock price forecast is 71.67% higher than the current stock price, while the lowest is $0.99 (+65.00%) and the highest is $1.09 (+81.67%).
Price Target: $1.03 (+71.67%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 16, 2026.
Analyst Ratings
The average analyst rating for SomnoMed stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Dec '25 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $1.00 | Buy | Maintains | $1.00 | +66.67% | Apr 16, 2026 |
| Morgans | Morgans | Buy Maintains $0.99 | Buy | Maintains | $0.99 | +65.00% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
122.63M
from 111.49M
Increased by 9.99%
Revenue Next Year
133.69M
from 122.63M
Increased by 9.02%
EPS This Year
0.01
from -0.02
EPS Next Year
0.03
from 0.01
Increased by 141.67%
Financial currency is AUD.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 124.6M | ||
| Avg | 122.6M | ||
| Low | 121.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 11.8% | ||
| Avg | 10.0% | ||
| Low | 8.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.01 | ||
| Avg | 0.01 | ||
| Low | 0.01 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.